Semaglutide(Suzhou Thery Pharma)

司美格鲁肽（苏州特瑞药业）

Report date: 2024/12/25 20:00:50

Base Information

Drug NameSemaglutide(Suzhou Thery Pharma)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightBody WeightObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Thery Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Thery Pharmaceutical Inc
Inactive CompaniesN/A
Active IndicationsOverweightBody WeightObesity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A